Clinical Trial

Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous human immunoglobulin (Newnorm) in patients with primary immunodeficiency diseases
Protocol Amendment History 1 change
notable Primary completion pushed: 2026-06 -> 2026-09 2026-07-17
Trial Details
NCT Number NCT04640142
Lead Sponsor Octapharma
Conditions Primary Immune Deficiency
Enrollment 50 participants
Start Date 2021-08-04
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-06